These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23900343)

  • 61. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
    Tzoupis H; Leonis G; Megariotis G; Supuran CT; Mavromoustakos T; Papadopoulos MG
    J Med Chem; 2012 Jun; 55(12):5784-96. PubMed ID: 22621689
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.
    Olomola TO; Klein R; Mautsa N; Sayed Y; Kaye PT
    Bioorg Med Chem; 2013 Apr; 21(7):1964-71. PubMed ID: 23415084
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Novel pyridinium-type fullerene derivatives as multitargeting inhibitors of HIV-1 reverse transcriptase, HIV-1 protease, and HCV NS5B polymerase.
    Kobayashi T; Yasuno T; Takahashi K; Nakamura S; Mashino T; Ohe T
    Bioorg Med Chem Lett; 2021 Oct; 49():128267. PubMed ID: 34271071
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Structure based prediction of binding affinity of human immunodeficiency virus-1 protease inhibitors.
    Kulkarni SS; Kulkarni VM
    J Chem Inf Comput Sci; 1999; 39(6):1128-40. PubMed ID: 10614027
    [TBL] [Abstract][Full Text] [Related]  

  • 67. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
    Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
    Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Active site binding modes of curcumin in HIV-1 protease and integrase.
    Vajragupta O; Boonchoong P; Morris GM; Olson AJ
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.
    Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; JerônimoLameira ; Maguire GE; Soliman ME
    J Enzyme Inhib Med Chem; 2013 Feb; 28(1):78-88. PubMed ID: 22339087
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative molecular field analysis (CoMFA), topomer CoMFA, and hologram QSAR studies on a series of novel HIV-1 protease inhibitors.
    Heidari A; Fatemi MH
    Chem Biol Drug Des; 2017 Jun; 89(6):918-931. PubMed ID: 27933723
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors.
    La Monica G; Lauria A; Bono A; Martorana A
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199858
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK
    J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
    Opera TI; Waller CL; Marshall GR
    Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
    Wlodawer A; Vondrasek J
    Annu Rev Biophys Biomol Struct; 1998; 27():249-84. PubMed ID: 9646869
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Finding the structural requirements of diverse HIV-1 protease inhibitors using multiple QSAR modelling for lead identification.
    Halder AK
    SAR QSAR Environ Res; 2018 Nov; 29(11):911-933. PubMed ID: 30332922
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Quantitative structure-activity relationship of some HIV-1 protease inhibitors: a Fujita-Ban type analysis.
    Mekapati SB; Sivakumar R; Gupta SP
    J Enzyme Inhib; 2001; 16(3):185-97. PubMed ID: 11697040
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.
    Yadav D; Paliwal S; Yadav R; Pal M; Pandey A
    PLoS One; 2012; 7(11):e48942. PubMed ID: 23145032
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.